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ABSTRACT
Objectives: The aim of our work was to assess the usefulness of maternal factors, ultrasound and placental function 
parameters during early pregnancy as predictors of birth weight in populations of healthy pregnant women and women 
suffering from pregestational diabetes.
Material and methods: A study group comprised 97 healthy women and 160 women with pregestational diabetes (PGDM, 
type 1), all in singleton pregnancy. Ultrasound examination was performed between weeks 11 and 14, and in weeks 20 and 
30 of gestation, based on recommendations of the Polish Society of Gynecologists and Obstetricians, Ultrasonography 
Division. We also checked uterine artery blood flow parameters. During the first trimester consultation, all patients were 
surveyed and the following data were  collected: age, BMI, reproductive history, comorbidities and smoking. We also col-
lected blood samples and assessed PlGF, PAPP-A, and BhCG levels.
Results: Our study showed that newborn birth weight negatively correlated with mother’s age, her diastolic blood pressure, 
PI of her uterine arteries and BhCG protein levels. Moreover, birth weight directly correlated with PlGF and PAPPA-A protein 
levels, and maternal early-pregnancy BMI.
Conclusions: LGA diagnosis in the first trimester of pregnancy allows for selection and modification of some risk factors 
and closer monitoring of endangered fetuses throughout the pregnancy, with emphasis on the perinatal period.
Parameters with confirmed usefulness in the prediction of birth weight in the first trimester included: maternal age, BMI, 
blood pressure, PAPP-A, BhCG and PlGF levels, fetal CRL and uterine artery PI.
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INTRODUCTION
Models of modern prenatal care aim at determining 
the risk of pregnancy-related complications during the first 
trimester. They also investigate any disorders related to the 
fetus growth. Numerous studies carried out on a large scale 
allowed for development of highly sensitive screening tests 
for fetal growth disorders based on using data from ultra-
sound examinations (carried out between weeks 11–13 + 6 of 
pregnancy), accompanied by tests of mother blood serum. 
Abnormal fetal growth, resulting in either large-for-ges-
tational age (LGA), small-for-gestational age (SGA) or in-
trauterine growth restriction (IUGR), is a common fetal 
complication in high risk pregnancy [1, 2]. Therefore, early 
assessment of fetal growth and risk factors for inadequate 
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fetal growth now gain considerable attention in the field of 
maternal-fetal medicine.
Maternal hyperglycemia is the main factor responsible 
for excessive fetal growth. Elevated maternal glucose levels 
intensify glucose transport to the fetus, which results in 
increased fetal production of insulin and insulin-like growth 
factors. This consequently leads to excessive development 
of adipose tissue in the developing fetus. Fetal growth un-
dergoes strong genetic regulation but it is also modified by 
intrauterine environment (epigenetic factors) that deter-
mines the newborn final weight [3–5]. The most important 
risk factors for fetal macrosomia are: maternal diabetes and 
obesity, older age, gestational hypertension, and pregnancy 
lasting over 42 weeks. Excessive weight in the fetus causes 
several complications during prenatal development, and 
perinatal and postnatal life. In the perinatal period, LGA is 
associated with more frequent obstructed labors, higher 
percentage of pelvic floor muscle and maternal anal sphinc-
ter injuries, shoulder dystocia with consequent paralysis of 
the shoulder plexus, hypoxia and neonatal death.
Long-term observations of children with macrosomia 
show that as adults they are more prone to becoming 
overweight or obese and more often suffer from diabetes 
and cardiovascular disorders. In children with birth weight 
exceeding 4000 g, higher frequency of insulin resistance, 
increased risk of metabolic syndrome, abnormal fasting 
blood glucose, and abnormal glucose tolerance in child-
hood are reported [6].
To reduce the risk of birth weight related complications, 
early identification of the risk group for fetal macrosomia 
and early elimination of potentially modifiable risk factors 
are important. The modern model of perinatal care called 
“an inverted pyramid” identifies early pregnancy as a period for 
perinatal risk assessment [7]. Thus, each pregnant woman is as-
signed to an appropriate risk group and specific interventions 
are commenced to reduce the identified risks. A risk analysis 
in early pregnancy also involves screening for abnormal fetal 
growth. An assessment model that draws upon data from 
a pregnancy history, nuchal translucency, and the levels of 
free β-human chorionic gonadotropin (β-hCG) and pregnan-
cy-associated plasma protein (PAPP-A) in the maternal serum 
between weeks 11–13 of pregnancy, identifies only about 35% 
of women who would give birth to LGA newborns. Moreover, 
false positive rate is approximately 10% [8]. Further research in 
this field increased sensitivity and specificity of LGA screening 
by introducing new biomarkers (Inhibin A, selectin E, PLGF), 
and accounting for additional data obtained during ultra-
sound examination (pulsatility index PI, of the uterine artery). 
Despite that, majority of LGA cases remain undetected until 
actual delivery. Furthermore, we lack a prognostic tool that 
discriminates between a constitutionally large but healthy 
newborn and a neonate with “intrauterine obesity”.
Objectives
The aim of our work was to assess the usefulness of 
maternal factors ultrasound and placental function param-
eters during early pregnancy as predictors of birth weight 
in populations of healthy pregnant women and women 
suffering from pregestational (type 1) diabetes. 
MATERIAL AND METHODS
The prospective observational study included 97 healthy 
pregnant women (non-PGDM) and 160 pregnant women 
with pregestational diabetes (PGDM, type 1), all in singleton, 
non-malformed pregnancy, monitored on an outpatient 
basis during the pregnancy period at the Hospital Outpatient 
Clinic of the Podhalanski Specialist Hospital in Nowy Targ, 
Poland, or undergoing antenatal care in a tertiary referral unit 
of the Department of Obstetrics and Women’s Diseases of 
the Poznan University of Medical Sciences, Poznan, Poland. 
All patients included in the study were informed about its pur-
pose and scope and gave their written consent to participate.
Monitoring consisted of three follow-up visits during 
the pregnancy: between weeks 11 and 13 + 6, and during 
weeks 20 and 30. At the first visit, data were collected from 
each patient using a questionnaire. It requested information 
about the patient’s age, BMI, reproductive history and co-
morbidities. It particularly focused on diabetes and its type, 
age of the patient at onset, pregnancy-induced hyperten-
sion, pre-eclampsia in previous pregnancies, and smoking.
The study, carried out between weeks 11 and 13 + 6 of 
pregnancy, aimed at assessing fetal anatomy and evaluating 
markers of chromosomal aberrations using the recommen-
dations of the Polish Society of Gynecologists and Obstetri-
cians, Ultrasonography Division (crown rump length — CRL, 
biparietal diameter — BPD, nuchal translucency — NT, nasal 
bone — NB, ductus venosus — DV), and uterine artery blood 
flow parameters (UtA PI — pulsatility index). Blood samples 
collected during the visits were centrifuged, aliquoted and 
transported to the ISO 9000 accredited Central Laboratory 
of Clinical Gynecology and Obstetrics Hospital in Poznań, 
where PlGF and PAPP-A protein concentrations, and β-hCG, 
PlGF and PAPP-A serum levels were determined in an im-
munofluorometric assay and DELFIA Xpress analyzer. β-hCG 
values were assessed using monoclonal antibodies labeled 
with a ruthenium complex.
We defined birth weight above the 90th percen-
tile for a gestational age and neonatal sex at delivery as 
a large-for-gestational age newborn (LGA). Birth weight 
below the 10th percentile for a gestational age at delivery 
and neonatal sex were defined as a small-for-gestational 
age newborn (SGA). Percentiles were calculated referring 
to the non- PGDM subgroup in the study.
Statistical analysis was carried out using SPSS for Win-
dows 14.0.0 (SPSS Inc. Chicago, USA) and MedCalc Statisti-
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cal Software, version 18.2.1 (MedCalc Software bvba, Os-
tend, Belgium; http://www.medcalc.org; 2018). Data were 
checked for normality and then appropriate parametric 
or nonparametric tests were used to check for differences 
between the variables studied in the PGDM and non-PGDM 
subgroups. Multiple regression models were built to identify 
predictors for the birth weight in the entire cohort, and for 
both researched groups. We used logistic regression and 
ROC analysis to identify predictors of abnormal birth weight, 
defined as large-for-gestational age or small-for-gestational 
age. Variables were presented as mean ± standard deviation 
or median. P < 0.05 was considered statistically significant.
RESULTS
Table 1 summarizes the characteristics of the study 
groups. Of the entire cohort, 9.7% of participants had 
pregnancy-related hypertensive disorders, 9.7% reported 
smoking during pregnancy, 30.7% were overweight or 
Table 1. Characteristics of the study groups
Variables Patient group Mean Standard deviation (SD) Median Min Max Mann-Whitney Test
Age [years]
PGDM 29.8 4.7 29.3 19.4 44.5
p = 0.030
non-PGDM 28.5 5.3 27.0 19.0 41.0
Height [cm]
PGDM 166.0 6.3 165.0 153.0 186.0
p = 0.569 
non-PGDM 165.2 6.0 165.0 150.0 176.0
Weight [kg]
PGDM 65.3 14.6 62.0 47.0 124.0
p = 0.227 
non-PGDM 66.2 12.4 62.9 44.6 99.0
BMI
PGDM 23.7 5.1 22.6 16.7 47.8
p = 0.161 
non-PGDM 24.3 4.7 23.0 17.6 39.0
Systolic BR
PGDM 112.3 14.6 111.9 80.0 150.8
p = 0.003
non-PGDM 107.6 12.8 105.0 80.0 145.0
Diastolic BP
PGDM 70.6 9.9 70.0 50.0 97.0
p = 0.006
non-PGDM 67.3 9.7 65.0 50.0 90.0
Mean BP
PGDM 84.5 11.0 83.3 60.0 112.9
p = 0.005
non-PGDM 80.7 9.9 79.2 60.0 106.7
Right UtA PI
(I trimester)
PGDM 1.55 0.63 1.44 0.46 3.57
p = 0.426 
non-PGDM 1.60 0.58 1.49 0.57 3.49
Left UtA PI
(I trimester)
PGDM 1.53 0.60 1.52 0.45 3.43
p = 0.455 
non-PGDM 1.55 0.47 1.51 0.53 2.82
Low UtAPI
PGDM 1.29 0.49 1.23 0.45 2.89
p = 0.225 
non-PGDM 1.20 0.40 1.17 0.40 2.64
High UtAPI 
PGDM 1.79 0.62 1.77 0.56 3.57
p = 0.001
non-PGDM 2.10 0.67 1.98 0.90 3.98
Mean UtAPI
PGDM 1.54 0.51 1.52 0.55 2.99
p = 0.469 
non-PGDM 1.59 0.44 1.52 0.85 2.88
CRL [mm]
PGDM 65.1 8.3 64.0 48.0 83.0
p = 0.186 
non-PGDM 63.4 10.9 64.5 45.0 86.0
NT [mm]
PGDM 1.38 0.33 1.40 0.70 2.50
p < 0.001
non-PGDM 2.49 8.40 1.70 1.00 83.00
β-hCG
U/l
PGDM 53.0 56.0 42.7 8.3 522.2
p = 0.033
non-PGDM 41.5 31.2 33.1 6.3 232.8
PAPP-A U/L
PGDM 3.07 1.98 2.77 0.22 9.43
p = 0.689 
non-PGDM 3.26 3.94 2.44 0.67 36.45
PLGF [pg/L]
PGDM 43.5 15.0 39.9 1.7 100.0
p < 0.001
non-PGDM 34.0 14.5 30.4 13.6 90.8
Birth weight [g]
PGDM 3388 596 3415 980 4660
p = 0.191 
non-PGDM 3314 512 3350 1660 4600
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obese (compared with 13.2% of our subgroup). In the PGDM 
subgroup, 10.1% of participants had vascular complications 
(retinopathy, and/or nephropathy). 
There were no statistically significant differences be-
tween patients with pre-gestational diabetes and nondia-
betic participants regarding height, body weight, and BMI, 
PI in the right and left uterine artery, the lowest and average 
PI value of the uterine artery, crown rump length (CRL), 
PAPP-A levels or child birth weight. 
Data concerning correlations between the fetal and 
maternal parameters collected during early pregnancy and 
neonatal body weight are summarized in Table 2.
We found that in the non-PGDM subgroup birth weight 
significantly correlated only with maternal BMI, whereas 
among the diabetic patients significant correlations were 
confirmed for maternal age, CRL, vascular flow and concen-
tration of placental proteins.
In order to investigate the influence of selected early 
pregnancy parameters on birth weight in the entire cohort, 
stepwise regression was built. The best-fit model for the 
entire cohort is presented in Table 3.
After investigating for early pregnancy maternal and 
fetal parameters, we found that PAPPA concentrations, early 
pregnancy maternal body weight and hypertensive status 
remained statistically significant predictors of birth weight 
across the entire study group.
In a separate analysis, we looked for predictors of abnormal 
fetal growth, defined as either LGA or SGA. In our study group, 
we had 39 cases of LGA out of 226 mother-infant pairs (17.2%, 
no data available for 31 patients). After investigating for fetal 
and maternal parameters, we confirmed that only mean UtAPI 
remained a statistically significant predictor of LGA (Tab. 4). 
However, we also identified several independent predictors of 
LGA in our cohort that included PlGF, NT, and CRL (Fig. 1 A–D). 
Table 2. Correlations between birth weight and fetal/maternal characteristics
Pairs of correlated variables
STUDY GROUP PGDM non-PGDM
R p R p R p
Birth weight [g] & Age -0.129 0.049 -0.165 0.044 -0.100 0.356
Birth weight [g] & BMI 0.076 0.247 0.014 0.861 0.224 0.039
Birth weight [g] & systolic BP 0.021 0.747 -0.040 0.626 0.067 0.543
Birth weight [g] & diastolic BP -0.028 0.674 -0.076 0.358 0.037 0.738
Birth weight [g] & Mean BP -0.002 0.978 -0.055 0.508 0.047 0.666
Birth weight [g] & right UtAPI -0.065 0.327 -0.109 0.194 0.032 0.770
Birth weight [g] & left UtAPI -0.168 0.014 -0.177 0.033 -0.131 0.282
Birth weight [g] & low UtAPI -0.087 0.189 -0.131 0.116 -0.010 0.925
Birth weight [g] & high UtAPI -0.131 0.048 -0.167 0.044 -0.022 0.839
Birth weight [g] & mean UtAPI -0.128 0.052 -0.161 0.054 -0.062 0.570
Birth weight [g] & CRL [mm] 0.085 0.194 0.164 0.046 -0.053 0.631
Birth weight [g] & NT [mm] 0.006 0.930 0.049 0.554 0.042 0.704
Birth weight [g] & B-hCG IU/L -0.043 0.516 -0.080 0.336 0.009 0.935
Birth weight [g] & PAPP-A U/L 0.119 0.072 0.258 0.002 -0.163 0.140
Birth weight [g] & PLGF [pg/L] 0.187 0.006 0.284 0.001 0.042 0.734
p — level of significance; R — Spearman’s rank correlation coefficient
Table 3. Predictors of birth weight in the entire cohort — multiple regression
Summary of dependent variable regression:   Birth weight [g]
R = 0.341 R2 = 0.116 correct; R2 = 0.102; F (5.185) = 3.9103; p < 0.0001; standard estimation error: 560.279
Regression model
Standardized coefficients Non-standardized coefficients
t (185) p
beta B SE
Intercept 2257.217 250.085 9.027 p < 0.0001
PAPPA serum level 0.274 79.907 21.711 3.680 p < 0.0001
Maternal body weight 0.309 13.397 3.341 4.010 p < 0.0001
Hypertensive disorders of pregnancy YES -0.149 -287.703 140.234 -2.052 p = 0.042
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In the entire cohort we had 24 cases of SGA (10.6%, 
no data available for 31 patients). None of the analyzed 
variables significantly predicted birth weight below the 
10th percentile. 
In a separate analysis of the subgroups, we identified 
several predictors of birth weight in PGDM subgroup that 
remained statistically significant after adjustment: the moth-
er’s age, gestational age at examination, glycemic levels 
below a pathological limit, and duration of diabetes. Data 
from the multiple regression model are presented in Table 5. 
To identify predictive factors for excessive fetal growth 
in diabetic pregnancy, we built a model of logistic regres-
sion with LGA as a dependent variable. After adjustments 
for fetal and maternal confounders, mean UtAPI and PAPPA 
serum level remained as statistically significant predictors 
of LGA in this subgroup (Tab. 6). However, we also identified 
CRL and PLGF as independent LGA predictors (Fig. 2 A–B). 
In PGDM subgroup, we had 17 cases of SGA. After adjusting 
for confounders, maternal PLGF serum level was found to 
be a statistically significant predictor of low birth weight 
but with a minimal actual impact on this outcome (Tab. 7). 
We also noted that PAPPA serum levels independently pre-
dicted SGA in this cohort (Fig. 3 A–B).
In a separate analysis of non-PGDM subgroup, none of 
the parameters contributed significantly to the risk of LGA. 
DISCUSSION
Early detection of pregnant women with high risk of 
fetal growth disorders allows for closer monitoring of these 
patients, possible modification of risk factors and informed 
decisions concerning the mode of delivery. Recent research 
in this field abounds in algorithms based on data obtained 
during the first trimester screening, supplemented with 
Table 4. Predictors of lga in the entire cohort — logistic regression
Logistic regression FSTEP model Regression coefficient B p Odds ratio (OR) 95% confidence interval for OR
Intercept 0.64 p = 0.329 1.90
mean UtAPI -1.496 p = 0.001 0.22 0.09 0.56
Table 5. Predictors of birth weight in Pgdm patients — multiple regression
Summary of dependent variable regression: Birth weight [g]
R = 0.454; R2 = 0.206 Correct; R2 = 0.182; F (6.133) = 6.2581; p < 0.00001; standard estimation error: 539.602
Regression model
Standardized coefficients Non-standardized coefficients
t (185) p
beta B SE
Intercept 860.804 1220.459 0.705 p = 0.482
PAPP-A U/L 0.353 103.3065 23.036 4.487 p < 0.0001
β-hCG IU/L -0.197 -2.015 0.791 -2.546 p = 0.012
Maternal height [cm] 0.196 18.402 7.251 2,.538 p = 0.012
Diastolic BP at the examination -0.182 -10.801 4.702 -2.297 p = 0.023
Table 6. Predictors of lga in Pgdm patients — logistic regression
Logistic regression FSTEP model Regression coefficient B p Odds ratio (OR) 95% confidence interval for OR
Intercept -0.379 p = 0.643 0.684
PAPP-A U/L 0.205 p = 0.043 1.23 1.01 1.50
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Figure 1. Independent predictors of LGA in the whole cohort
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additional data from ultrasound examination and on plasma 
protein concentrations.
In 2013, Papastefanou et al. performed prenatal ex-
aminations in 702 first trimester patients. They created 
a diagnostic model in which significant, independent SGA 
predictors included patient height, multiparity, smoking, 
assisted reproduction, CRL, NT and PAPP-A and β-hCG 
levels. They also found that the weight and height of the 
pregnant women, cigarette smoking, and CRL and NT levels 
were significant, independent predictors of LGA. Sensitivity 
of both models was relatively low — 48% for LGA and 55% 
for SGA [9]. The importance of the body mass index in LGA 
prediction was confirmed in another prospective screening 
study, based on examination of 41.577 pregnancies. Re-
gression analysis showed a significant contribution from 
maternal BMI, in addition to maternal characteristics and 
obstetric history, in the prediction of subsequent delivery of 
small and large for gestational age neonates. The risk of LGA 
increased exponentially with increasing maternal BMI [10].
In 2016, Frick et al. published an observational study 
of a large cohort of pregnant women who were having 
fetal growth monitored throughout their pregnancies. The 
likelihood of developing LGA grew with increasing weight 
and height of the mothers, and decreased in tobacco-
smoking and nulliparous women. Higher LGA risk was also 
found in patients with pre-gestational diabetes type 1, 
but dropped in patients with chronic hypertension. In 
multiparous women, LGA risk increased if LGA newborn 
was delivered before, and decreased in patients with 
previous gestational diabetes and short interval between 
consecutive pregnancies. The screening study was solely 
based on medical history data taken from 76.300, 54.999, 
25.727 and 6.181 singleton pregnancies at 11–13, 19–24, 
30–34, and 35–37 weeks’ gestation, respectively. Screening 
by maternal factors at 11–13 weeks predicted 32%, 44% and 
60% of LGA > 95th at false-positive rates (FPRs) of 5%, 10% 
and 20%, respectively. With the addition of fetal biometry, 
the detection rates improved to 37%, 51% and 68% at 
19–24 weeks, 50%, 65% and 81% at 30–34 weeks and 60%, 
73% and 85% at 35–37 weeks at FPRs of 5%, 10% and 20%, 
respectively. The addition of biomarkers did not improve the 
detection rates achieved when screening by a combination 
of maternal history and fetal biometry [11].
An LGA prediction algorithm similar to that mentioned 
above was used in an Italian study of 72 pregnant 
women between weeks 11–14 of pregnancy. The LGA 
prediction used historical data and PAPP-A concentration 
levels. Maternal growth, age, smoking, assisted 
reproduction and PAPP-A levels were found to be 
important, independent predictors of LGA [12]. In another 
study, Gonzalez et al. conducted a prenatal examination 
of 2097 pregnant women, including a Doppler study of 
the uterine artery in the first trimester and an assessment 
of fetal growth and the uterine artery Doppler in the 
second trimester. The study algorithm based on maternal 
history, PAPP-A protein concentrations, and β-hCG, 
NT, and PI values in the uterine arteries, allowed for 
identification of 30.2% of LGA cases, with a false positive 
rate of 10%. When data from the second trimester were 
added, the sensitivity increased to 56.2% with FPR of 
20% [13]. Another biomarker that turned out useful in 
the prediction of macrosomic neonates was adiponectin. 
Examination of 350 cases showed that in the macrosomic 
group the median serum adiponectin was significantly 
lower than in the non-macrosomic controls. A detection 
rate of macrosomia, based on maternal characteristics 
and obstetric history was 34.6% with false positive rate of 
Table 7. Predictors of sga in Pgdm patients — logistic regression
Logistic regression FSTEP model Regression coefficient B p Odds ratio (OR) 95% confidence interval for OR
Intercept 0.147 p = 0.880  0.95  




















0   10         30   40  50         70  80        100
100-Specicity
PIGFpgl

















0   10         30   40  50         70  80        100
100-Specicity
CRLmm
























0    10           30   40   50          70   80          100
100-Specicity
PIGFpgl

















0    10           30   40   50          70   80          100
100-Specicity
PAPPAUL




Figure 3. Predictors of SGA in PGDM patients
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10%. Inclusion of adiponectin to this algorithm increased 
the detection rate to 38.2% [14].
Boucoiran at al. used only the parameters from the 
first trimester screening for aneuploidies to predict the 
birth weight. They examined 4110 patients in a singleton 
pregnancy. NT was significantly higher in LGA group as 
compared with the unaffected group but biomarkers (PAPPA 
and BhCG) were at the same levels in both groups. After 
controlling for gestational age, maternal weight, smoking 
status, ethnicity, and fetal sex, first-trimester markers 
contributed to the prediction of birth weight in a multiple 
linear model but did not significantly improve the prediction 
of LGA as compared with maternal characteristics alone [15].
There are few studies referring to growth disorders in 
the fetuses of mothers with pre-gestational diabetes, which 
used plasma protein concentrations and data from prenatal 
ultrasound examination between weeks 11–14 of pregnancy 
in their algorithm. The most frequently assessed predictors 
of growth disorders in such fetuses were fasting glycemia 
and gyrated hemoglobin concentrations. Some information 
about the risk of LGA and fetal macrosomy in pregnancies 
complicated by a metabolic syndrome and obesity can be 
found in the first trimester screening carried out by Migda et 
al. in 123 Caucasian patients with the metabolic syndrome. 
In that study, BMI above 25.5 was found an important risk 
factor for excessive fetal weight. Mother blood glucose and 
concentrations of adiponectin and soluble E-selectin were 
predictive of LGA and fetal macrosomia. The mother weight 
of or exceeding 67 kg in the first trimester showed high sen-
sitivity and specificity in detecting LGA and macrosomia [16]. 
However, that study investigated a completely different 
population than ours.
Based on our cohort, we can conclude that placentation 
and placental function during early pregnancy strongly 
affect fetal growth, particularly in PGDM complicated preg-
nancy. Importantly, early pregnancy vascular function seems 
to be even more crucial for fetal growth than maternal 
pre-pregnancy glycemic control. The latter needs to be 
achieved if a reduced risk of fetal malformation or miscar-
riage is aimed at, while uteroplacental capacity ensures 
adequate transfer of oxygen and nutrients. 
Our observations confirm that genetic potential (seen as 
CRL), uteroplacental vascular capacity (measured as UtAPI), 
and placental function (measured as serum levels of specific 
placental proteins) shape the growth trajectory for fetus-
es. Those predictors, supported by data commonly available 
from the patient’s history (age, BMI, and blood pressure) 
can be used in the algorithm for the first trimester. In our 
study, birth weight of the newborn negatively correlated 
with the age of the mother, her diastolic blood pressure, 
PI of the  uterine artery and BhCG protein levels. PlGF and 
PAPPA-A protein levels and maternal early-pregnancy BMI 
correlated positively with birth weight of the newborn. Im-
portantly, using an LGA prediction algorithm in the first tri-
mester of pregnancies complicated by PGDM, we are able 
to estimate the baseline risk of fetal growth disorders in the 
diabetic population before the maternal glycemia affected 
the fetal growth trajectory.
CONCLUSIONS
1. LGA diagnosis in the first trimester of pregnancy al-
lows for the selection and modification of some risk 
factors and closer monitoring of endangered fetuses 
throughout the pregnancy, with emphasis on the peri-
natal period.
2. Parameters with confirmed usefulness in the prediction 
of the birth weight in the first trimester include maternal 
age, BMI, blood pressure, PAPP-A, BhCG and PlGF values; 
CRL measurement and uterine artery PI values.
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